Vision & Mission

Our vision is to discover new, safe, and effective medications for treating neurological disorders.

Our mission is to develop novel proprietary small molecule to treat neuropathic pain.

Significance & Justification

  • Neuropathic pain resulting from diabetes or cancer is a widespread and debilitating condition affecting 5% of people and astonishing  25% of diabetics worldwide.
  • Current medications are not satisfactory due to poor efficacy or undesirable side effects.
  • Clear & convincing evidence that both sigma (σ1) and serotonin (5-HT7) receptors directly participate in the pain pathway.
  • Very profitable opportunity.  Current market size is $2.4 Billion.  Expected to grow to $7.5 Billion in 2020 in 7 major markets.


  • Daya’s innovative technology involves targeting both σ1 and 5-HT7 receptors with a single molecule to get an additive or synergistic effect.
  • The dual σ1/ 5-HT7 receptor strategy for developing pain medication represents a unique and pioneering concept that has not been disclosed by others.
  • Provisional patent application covering the composition of matter and use has been filed.

Current Results

  • Proof of concept established.  Daya has identified a new, proprietary, small molecule lead, DDD-028, which is orally active.
  • DDD-028 binds selectively to σ1 and 5-HT7 receptors with Ki’s of 220 nM and 195 nM respectively.
  • In off-target receptor profiling studies, DDD-028 shows no opioid activity.
  • In vivo, DDD-028 is effective in reversing neuropathic pain in mouse  model at very low dose of 1.00 mg/kg.
  • DDD-028 is about 10-fold more potent than morphine and 180-fold more potent than gabapentin.

Future Plans (Preclinical Evaluation)

  • Conduct pharmacokinetic, ADME, bioavailability, and toxicity studies.
  • Evaluate DDD-028 in several neuropathic pain models:  diabetic neuropathy, cancer pain, .
  • Optimize manufacturing process under GLP/GMP protocol.
  • File investigational new drug application (IND) with USFDA.